New hope for Hard-to-Treat myeloma patients through expanded access program
NCT ID NCT05757973
First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 28 times
Summary
This program gives talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. Participants must have tried all available treatments and cannot join a clinical trial. The goal is to provide access to this therapy before it is fully approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.